Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

AbbVie (ABBV) is trending on Zacks.com, with a current Zacks Rank #3 (Hold), suggesting near-term performance in line with the broader market. The consensus EPS estimate for the current quarter is $3.24, a 22.3% year-over-year increase, and revenue is projected to reach $14.98 billion, up 3.6% year-over-year; full-year EPS is estimated at $12.28 (+21.3% YoY) and $14.06 the following year (+14.4% YoY), with revenue reaching $60.04 billion (+6.6% YoY) and $64.99 billion (+8.2% YoY) respectively. AbbVie's Zacks Value Style Score is B, indicating the stock is trading at a discount compared to its peers.

Analysis

AbbVie (ABBV) has recently been a frequently searched stock, yet its shares have underperformed in the past month with a +0.8% return, compared to the Zacks S&P 500 composite's +6.9% and the Zacks Large Cap Pharmaceuticals industry's +8.0%. The stock currently holds a Zacks Rank #3 (Hold), suggesting its near-term performance may align with the broader market. AbbVie is projected to report earnings of $3.24 per share for the current quarter, a significant +22.3% year-over-year increase, with the Zacks Consensus Estimate for this period having risen by +1.7% over the last 30 days. For the current fiscal year, consensus EPS stands at $12.28, reflecting a +21.3% YoY change, while the estimate for the next fiscal year is $14.06, a +14.4% increase, though both annual estimates have been stable over the past month. Revenue forecasts are also positive, with an estimated $14.98 billion for the current quarter (+3.6% YoY), $60.04 billion for the current fiscal year (+6.6% YoY), and $64.99 billion for the next fiscal year (+8.2% YoY). AbbVie has a consistent history of exceeding expectations, beating consensus EPS and revenue estimates in each of the last four quarters; its most recent reported quarter saw revenues of $13.34 billion (+8.4% YoY and a +3.39% surprise) and EPS of $2.46 (a +2.93% surprise). Furthermore, AbbVie's Zacks Value Style Score of B indicates it is currently trading at a discount compared to its peers.

Key Decisions for Investors

• Investors should weigh AbbVie's strong projected earnings growth and consistent history of exceeding analyst expectations against its current Zacks Rank #3 (Hold) and recent share price underperformance relative to the market and its sector.
• The stock's B grade on the Zacks Value Style Score suggests it may be trading at an attractive discount to its peers, potentially offering a favorable entry point for value-focused investors.
• It is advisable to monitor upcoming earnings announcements and any further revisions to consensus estimates, as sustained positive trends could serve as catalysts for improved stock performance despite the neutral Hold rating.